Key Highlights
- Lumata Health raises $23M in Series B funding, totaling $36M to date.
- Co-led by LRVHealth, McKesson Ventures, and Cencora Ventures, with continued support from Cortado Ventures.
- The investment will expand Lumata’s AI-driven platform, improving adherence to vision-saving treatments.
- Proven impact: Up to 800 additional eye injections annually per 1,000 patients, reducing preventable blindness.
- Strong industry partnerships with leading eye care networks to enhance patient outcomes.
Source: Business Wire
Notable Quotes
- “We are thrilled to partner with investors who share our vision for a smarter, more effective approach to preventing blindness from chronic eye diseases.” — Landon Grace, CEO at Lumata Health
- “By combining advanced technology, predictive analytics, and compassionate care, the company is reshaping how chronic eye diseases are managed and ensuring that more patients retain their vision for years to come.” — Ellen Herlacher, Partner at LRVHealth
- “Lumata’s proactive, end-to-end solution not only improves patient outcomes, it creates a win-win scenario for everyone involved in the care continuum.” — Michelle Snyder, Partner at McKesson Ventures
Why This Matters
Vision loss is a growing public health crisis, with conditions like glaucoma and diabetic retinopathy on the rise. While effective treatments exist, systemic barriers prevent timely care for millions. Lumata Health’s AI-driven, patient-centric approach is proving to be a game changer, improving adherence, reducing healthcare costs, and ensuring more patients retain their vision. With this new funding, Lumata is poised to expand its impact and drive transformative change in ophthalmology care.
